MEDNAX: Q1 included $14M in parity revenue that contributed 4c to EPS
Reports Q1 same-unit growth from net reimbursement-related factors 3.4%. This was principally due to the favorable impact of the parity revenue and continued modest improvements in reimbursements received from third-party commercial payors resulting from the company’s ongoing contract renewal process, slightly offset by a decrease in revenue from a shift in payor mix to government payors from commercial payors, year-over-year.
Terms and Privacy Policy